Front. Pharmacol.Frontiers in PharmacologyFront. Pharmacol.1663-9812Frontiers Media S.A.10.3389/fphar.2018.01385PharmacologyCorrectionCorrigendum: Evaluation of Marbofloxacin in Beagle Dogs After Oral Dosing: Preclinical Safety Evaluation and Comparative Pharmacokinetics of Two Different TabletsLeiZhixin123LiuQianying123YangBing12KhaliqHaseeb2AhmedSaeed23FanBowen12CaoJiyue23*HeQigai1*1State Key Laboratory of Agriculture Microbiology, College of Veterinary Medicine, Huazhong Agriculture University, Wuhan, China2Department of Veterinary Pharmacology, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan, China3National Reference Laboratory of Veterinary Drug Residues and MAO Key Laboratory for Detection of Veterinary Drug Residues, Huazhong Agriculture University, Wuhan, China
Edited and reviewed by: Yurong Lai, Gilead (United States), United States
*Correspondence: Jiyue Cao caojiyue2@163.comQigai He he628@mail.hzau.edu.cn
This article was submitted to Drug Metabolism and Transport, a section of the journal Frontiers in Pharmacology
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
A Corrigendum on Evaluation of Marbofloxacin in Beagle Dogs After Oral Dosing: Preclinical Safety Evaluation and Comparative Pharmacokinetics of Two Different Tablets by Lei, Z., Liu, Q., Yang, B., Khaliq, H., Ahmed, S., Fan, B., et al. (2018). Front. Pharmacol. 9:306. doi: 10.3389/fphar.2018.00306fluoroquinolonesmarbofloxacinpharmacokineticsbeagle dogsbioavailabilitytoxicity
In the original article, there was a mistake in Figure 4 as published. Information in Figure 4A was lost, due to a decimal error in the figure axis. The corrected Figure 4 appears below. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
The HPLC method for MBF quantification in plasma. (A) Blank plasma sample, (B) plasma sample at the LLOQ of 0.05 μg/ml, (C) plasma sample after oral administration of Petsen at the point of 16 h, (D) plasma sample after i.v administration of MBF at the point of 16 h. MBF at the peak time of 6.3 min.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.